|
The safety information regarding the use of Xeloda® (capecitabine).
|
04 June 2015 |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has endorsed restrictions on combining different classes of medicines that act on the renin-angiotensin system (RAS)
|
04 June 2015 |
|
Letter concerning to timelines for adverse drug reaction reporting
|
03 June 2015 |
|
In addition to our letter N0401126314 dated on 30.10.2014
|
03 March 2015 |
